Immunohistochemical Detection of Promyelocytic Leukemia Zinc Finger and Histone 1.5 in Uterine Leiomyosarcoma and Leiomyoma

Abstract

Objectives:

The accurate distinction of leiomyoma from leiomyosarcoma is essential for patient management. However, the distinction can be difficult to make, particularly in tissue biopsy samples. Immunohistochemistry has been established as a useful technique to aid in the diagnosis of malignancies. The advantages of immunohistochemical studies are their ease of use and interpretation. This study is the first to evaluate the utility of the promyelocytic leukemia zinc finger (PLZF) protein and the histone 1.5 (H1.5) protein as potential diagnostic immunohistochemical markers for distinguishing leiomyosarcoma from leiomyoma.

Methods:

Tissue samples from 21 leiomyosarcomas and 26 leiomyomas were studied. The student t-test and the Fisher exact test were used to calculate the differences in staining between the 2 groups.

Results:

Statistically significant differences were found in the staining indices of anti-PLZF and anti-H1.5 when comparing benign and malignant tumors (P < .0001 and P < .0001, respectively). The mean H1.5 staining score in leiomyosarcomas was 158.3, compared to 28.3 in leiomyomas. The mean PLZF score in leiomyosarcomas was 1.5 in contrast to 71.5 in leiomyomas. For H1.5 at a score ≥60, the sensitivity and specificity were 90.5% and 84.6%, respectively. For PLZF, a score ≤15 had a test sensitivity and specificity of 100% and 80.8%, respectively. This suggests that staining for H1.5 or PLZF can serve as a good screening test. Additionally, combining the 2 immunostains results in a sensitivity and specificity of 90.5% and 97.5%, respectively, in differentiating between leiomyoma and leiomyosarcoma.

Conclusions:

We describe immunostaining for PLZF and H1.5 in benign and malignant uterine smooth muscle tumors. Statistically significant differences in staining patterns were found, suggesting utility in distinguishing leiomyosarcomas from leiomyomas.

Keywords

leiomyosarcoma leiomyoma promyelocytic leukemia zinc finger (PLZF) protein histone H1.5 protein

Get full access to this article

View all access options for this article.

References

Charles

Henry

JN.

Mesenchymal tumors of the uterus. In: Kurman

Hedrick

Ronnett

, eds. Blaustein's Pathology of the Female Genital Tract. New York: Springer Verlag; 2002:561.

Parker

Berek

. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstetrics Gynecol. 1994;83(3):414–448.

Harlow

Weiss

Lofton

. The epidemiology of sarcomas of the uterus. J Natl Cancer Instit. 1986;76(3):399–402.

Leibsohn

d'Ablaing

Mishell

Jr, Schlaerth

. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162(4):968–974.

D'Angelo

Prat

. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131–139.

Fattaneh

Peter

. Pathology and Genetics of Tumours of the Breast and Female Genital Organs (WHO/IARC Classification of Tumours). Lyon: IARC Press; 2003.

Toledo

Oliva

. Smooth muscle tumors of the uterus: a practical approach. Arch Pathol Lab Med. 2008;132(4):595–605.

O'Neill

McBride

Connolly

McCluggage

. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology. 2007;50(7):851–858.

Tse

Tam

. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol. 2010;17(2):91–112.

10.

Hong

Shimada

Uchida

. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med. 2001;8(2):141–148.

11.

Moore

Yoshida

Rico

Haseman

Dixon

. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice. Exp Toxicol Pathol. 2000;52(3):195–200.

12.

Gokaslan

Turkeri

Kavak

. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005;59(1):36–40.

13.

Hall

Teneriello

Taylor

. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997;65(2):330–335.

14.

Mittal

Chen

Wei

. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol. 2009;22(10):1303–1311.

15.

Chen

Yang

. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27(3):326–332.

16.

Lee

Turbin

Sung

. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol. 2009;22(12):1519–1531.

17.

Yeyati

Shaknovich

Boterashvili

. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene. 1999;18(4):925–934.

18.

Fahnenstich

Nandy

Milde-Langosch

. Promyelocytic leukaemia zinc finger protein (PLZF) is a glucocorticoid- and progesterone-induced transcription factor in human endometrial stromal cells and myometrial smooth muscle cells. Mol Hum Reprod. 2003;9(10):611–623.

19.

Koken

Reid

Quignon

. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci U S A. 1997;94(19):10255–10260.

20.

Licht

Shaknovich

English

. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene. 1996;12(2):323–336.

21.

Hechtman

Beasley

Kinoshita

Hao

Burstein

. Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study. Hum Pathol. 2013;44(7):1400–1405.

22.

Shaknovich

Yeyati

Ivins

. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol. 1998;18(9):5533–5545.

23.

Cheung

Pei

Jhanwar

Pass

Testa

. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene. 2010;29(11):1633–1640.

24.

Felicetti

Bottero

Felli

. Role of PLZF in melanoma progression. Oncogene. 2004;23(26):4567–4576.

25.

Hizume

Yoshimura

Takeyasu

. Linker histone H1 per se can induce three-dimensional folding of chromatin fiber. Biochemistry. 2005;44(39):12978–1289.

26.

Happel

Doenecke

. Histone H1 and its isoforms: contribution to chromatin structure and function. Gene. 2009;431(1-2):1–12.

27.

Sato

Takahashi

Asamoto

. Histone H1 expression in human prostate cancer tissues and cell lines. Pathology. international 2012;62(2):84–92.

28.

Chen

Zelent

Tong

. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest. 1993;91(5):2260–2267.

29.

Reid

Gould

Brand

. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood. 1995;86(12):4544–4552.

30.

Barna

Hawe

Niswander

. Plzf regulates limb and axial skeletal patterning. Nat Genet. 2000;25(2):166–172.

31.

Leitao

Jr, Hensley

Barakat

. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol. 2012;124(3):558–562.

32.

Fan

Nikitina

Zhao

. Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. Cell. 2005;123(7):1199–1212.

33.

Shen

Gorovsky

. Linker histone H1 regulates specific gene expression but not global transcription in vivo. Cell. 1996;86(3):475–483.

34.

Hill

. Influence of linker histone H1 on chromatin remodeling. Biochem Cell Biol. 2001;79(3):317–324.

35.

Lee

Habas

Abate-Shen

. MSX1 cooperates with histone H1b for inhibition of transcription and myogenesis. Science. 2004;304(5677):1675–1678.

36.

Terme

Sese

Millan-Arino

. Histone H1 variants are differentially expressed and incorporated into chromatin during differentiation and reprogramming to pluripotency. J Biol Chem. 2011;286(41):35347–35357.